Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Purple Biotech Ltd. Capital/Financing Update 2017

Jul 15, 2017

7004_rns_2017-07-15_941262d4-348e-4db6-a255-9f294dcd8121.htm

Capital/Financing Update

Open in viewer

Opens in your device viewer

_________ false

����� ����� ������ ��"� 2 352
KITOV PHARMACEUTICALS HOLDINGS LTD
Corporation no: 520031238 10994
- - -
Israel Securities Authority Tel Aviv Stock Exchange C004 ( Public ) Reported via MAGNA: 15/07/2017
www.isa.gov.il www.tase.co.il Reference: 2017-02-073617 Time of broadcast: 22:06 21:57:28

Immediate report on other matterDon't use this form if there is more adequate one

PROSPECTUS SUPPLEMENT (to Prospectus dated December 14, 2016) Filed Pursuant to Rule 424(b)(5) Registration No. 333-215037 ����� ������ ������ �� ������ ����� ������ ���� �� ����� ����"� ���� ������� ���� �� ����� ��� ����� ������ ����� ����� ����� 2017. ��� �� ���� ����� ���� �� ����� ����� ����� ������ ������ ���� �� ������ ������ ���� �� �����, ��� ����� ����� �� ����� ������ ���� ��� ����� �� ���� �����, �� �� ����, ����� �� ����� ���� ����� ����� ���� ����� ���� ������ �� ���� �������� ����� ����� ������ ��� ��� ����� �� ���� �����
Attached file ProSupp_2017-07-13_isa.pdf
The submission by the Company to the Israel Securities Authority and the Tel Aviv Stock Exchange of a copy of a U.S. prospectus supplement originally filed by the Company with the United States Securities Exchange Commission pursuant to Rule 424(b)(5) filed should not be deemed an admission by the Company that such submission is required of the Company under the Securities Law 5728-1968 and the Securities Regulations (Periodic and Immediate Reports of Foreign Corporation)5761-2000, nor an admission by the Company that this submission is necessarily being delivered pursuant to the aforesaid laws and regulations.
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM Date of revision of form structure: 28/06/2017
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: [email protected]   Company site: www.kitovpharma.com
Previous names of reporting entity: MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: BEN-TZVI ABRAHAM SHLOMO Position of Signatory in the reporting corporation: General Counsel & Company Secretary Name of Employer Company:
Address: Menachem Begin St, Azrieli Towers Round Tower 132, Floor 23 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: [email protected] 1
Israel